Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abrilumab - Amgen/AstraZeneca

Next Previous
Drug Profile

Abrilumab - Amgen/AstraZeneca

Alternative Names: Abrilimumab; AMG-181; Anti-α4β7 integrin monoclonal antibody; MEDI-7183

Latest Information Update: 05 Nov 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Integrin alpha4beta7 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Crohn's disease; Ulcerative colitis

Most Recent Events

  • 10 Apr 2018 AstraZeneca completes a phase II trial for Ulcerative colitis in Japan (SC) (NCT01959165)
  • 10 Apr 2018 Amgen completes a phase II trial for Ulcerative colitis in USA, Canada, Australia, United Kingdom, Austria, Belgium, Czech Republic, Denmark, Estonia, France, Germany, Greece, Hungary, Italy, Latvia, Netherlands, Poland, Norway, Switzerland and Russia (SC) (NCT01694485)
  • 10 Apr 2018 Amgen completes a phase II trial for Crohn's disease in USA, Canada, European Union and Switzerland (NCT01696396)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top